Ambramycin
Ambramycin is a tetracycline antibiotic historically indicated for infections caused by susceptible strains of specific organisms, such as:
- Streptococcus pneumoniae
- Mycoplasma pneumoniae
- Chlamydia trachomatis
Structurally related to other tetracyclines, it has largely been superseded by agents with improved pharmacokinetics and safety profiles, including:
- Doxycycline
- Minocycline
- Eravacycline
- Sarecycline
Ambramycin is not currently listed in the European Medicines Agency (EMA) or U.S. Food and Drug Administration (FDA) databases, suggesting it is no longer authorized or actively marketed in the EU or USA. No recent clinical trials involving Ambramycin are registered on ClinicalTrials.gov, and no safety updates or SmPCs are available via the Electronic Medicines Compendium or Drugs.com. This supports its classification as a legacy antibiotic.
By Megan Lee
Developed by EPG Health for Medthority, independently of any sponsor.
of interest
are looking at
saved
next event
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
